{"id":56427,"date":"2023-05-02T13:04:34","date_gmt":"2023-05-02T11:04:34","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/"},"modified":"2023-05-02T13:04:34","modified_gmt":"2023-05-02T11:04:34","slug":"xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/","title":{"rendered":"Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023"},"content":{"rendered":"
\n

\nConference call and webcast at 8:30am ET<\/i><\/p>\n

CHICAGO–(BUSINESS WIRE)–#GvokeHypoPen<\/a>–Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, May 9, 2023. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company\u2019s financial and operational results.<\/p>\n

<\/a><\/p>\n

\nTo pre-register for the call, please go to the following link: https:\/\/www.netroadshow.com\/events\/login?show=148ea405&confId=49077<\/a><\/p>\n

\nAfter registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, June 8, at US:1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 104892<\/p>\n

\nTo join the webcast, please visit \u201cEvents\u201d on investor relations page of the Company\u2019s website at www.xerispharma.com<\/a> or use this link: https:\/\/events.q4inc.com\/attendee\/964102801<\/a><\/p>\n

\nAbout Xeris Biopharma Holdings, Inc.<\/b><\/p>\n

\nXeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke\u00ae<\/sup>, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis\u00ae<\/sup>, a proven therapy for primary periodic paralysis; and Recorlev\u00ae<\/sup> for the treatment of endogenous Cushing\u2019s syndrome. Xeris has a diverse pipeline of development and partnered programs using its formulation sciences, XeriSol\u2122 and XeriJect\u2122, to support long-term product development and commercial success.<\/p>\n

\nXeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com<\/a>, or follow us on Twitter<\/a>, LinkedIn<\/a> or Instagram<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact<\/b>
Allison Wey
\n
Senior Vice President, Investor Relations and Corporate Communications
\n
awey@xerispharma.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Conference call and webcast at 8:30am ET CHICAGO–(BUSINESS WIRE)–#GvokeHypoPen–Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2023 financial results before the open of the U.S. financial markets … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56427","6":"format-standard","7":"category-industry"},"yoast_head":"\nXeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Conference call and webcast at 8:30am ET CHICAGO–(BUSINESS WIRE)–#GvokeHypoPen–Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2023 financial results before the open of the U.S. financial markets ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-02T11:04:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230502005125\/en\/1778742\/21\/xeris_BIOPHARMA_TM_L.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023\",\"datePublished\":\"2023-05-02T11:04:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/\"},\"wordCount\":334,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502005125\\\/en\\\/1778742\\\/21\\\/xeris_BIOPHARMA_TM_L.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/\",\"name\":\"Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502005125\\\/en\\\/1778742\\\/21\\\/xeris_BIOPHARMA_TM_L.jpg\",\"datePublished\":\"2023-05-02T11:04:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502005125\\\/en\\\/1778742\\\/21\\\/xeris_BIOPHARMA_TM_L.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502005125\\\/en\\\/1778742\\\/21\\\/xeris_BIOPHARMA_TM_L.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/","og_locale":"en_US","og_type":"article","og_title":"Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023 - Pharma Trend","og_description":"Conference call and webcast at 8:30am ET CHICAGO–(BUSINESS WIRE)–#GvokeHypoPen–Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2023 financial results before the open of the U.S. financial markets ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-05-02T11:04:34+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230502005125\/en\/1778742\/21\/xeris_BIOPHARMA_TM_L.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023","datePublished":"2023-05-02T11:04:34+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/"},"wordCount":334,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230502005125\/en\/1778742\/21\/xeris_BIOPHARMA_TM_L.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/","url":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/","name":"Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230502005125\/en\/1778742\/21\/xeris_BIOPHARMA_TM_L.jpg","datePublished":"2023-05-02T11:04:34+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230502005125\/en\/1778742\/21\/xeris_BIOPHARMA_TM_L.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230502005125\/en\/1778742\/21\/xeris_BIOPHARMA_TM_L.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/xeris-biopharma-to-report-first-quarter-2023-financial-results-on-may-9-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56427"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56427\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}